Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Bio-Thera Starts Phase I Trial of Nectin-4 ADC for Solid Tumors

publication date: Mar 14, 2023

Guangzhou's Bio-Thera Solutions has started a China Phase I trial of BAT8007, an antibody-drug conjugate (ADC) that targets Nectin-4. The trial will enroll patients with advanced solid tumors to study the safety and tolerability of BAT8007 while determining the recommended Phase II dose (RP2D) of the candidate. The trial will also evaluate the pharmacokinetics and preliminary efficacy in patients. Bio-Thera said Nectin-4 is overexpressed in urothelial carcinoma, breast cancer, non-small cell lung cancer, pancreatic cancer, esophageal cancer and head and neck cancer. More details....

Stock Symbol: (SHA: 688177)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital